Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. (Nasdaq: DYN) is a clinical-stage biotechnology company developing treatments for genetically driven neuromuscular diseases. Its FORCE platform uses a transferrin receptor 1-binding antibody fragment, a linker and a therapeutic payload to target delivery to muscle tissue and potentially the… From the company’s description.
In fiscal 2025, Dyne Therapeutics, Inc. reported a net loss of $446.21M. Operations used $403.21M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Dyne Therapeutics, Inc. does
In the company’s own words
Dyne Therapeutics, Inc. (Nasdaq: DYN) is a clinical-stage biotechnology company developing treatments for genetically driven neuromuscular diseases. Its FORCE platform uses a transferrin receptor 1-binding antibody fragment, a linker and a therapeutic payload to target delivery to muscle tissue and potentially the central nervous system; payloads include oligonucleotides and enzymes. The company’s pipeline focuses on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), facioscapulohumeral dystrophy (FSHD) and Pompe disease. Its lead candidates, z-rostudirsen for DMD and z-basivarsen for DM1, are in global Phase 1/2 trials; DYNE-302 is advancing toward clinical development for FSHD, and the company is developing a Pompe candidate. DMD programs use PMOs designed to promote exon skipping, while the DM1 candidate uses an antisense oligonucleotide to reduce toxic DMPK RNA. Dyne has global commercial rights to its programs and employs more than 250 people, as of the fiscal year ended December 31, 2025. Its website is https://www.dyne-tx.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 1818794
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Dyne Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Dyne Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Dyne Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Dyne Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Dyne Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”